{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:58:02Z","timestamp":1768031882954,"version":"3.49.0"},"reference-count":39,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.5582\/ddt.2025.01095","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:07:53Z","timestamp":1765404473000},"page":"378-388","source":"Crossref","is-referenced-by-count":0,"title":["Real-world use of non-oral administration of oral anticancer agents &lt;i&gt;via&lt;\/i&gt; the simple suspension method in Japanese patients with cancer: A nationwide claims-based analysis"],"prefix":"10.5582","volume":"19","author":[{"given":"Hiroaki","family":"Ohta","sequence":"first","affiliation":[{"name":"Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Yasu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kav S, Fleury M, Fernandez-Ortega P, Manzullo EF, Kerr KA, DeGennaro R, Ginex PK. 15 years supporting adherence to oral anti-cancer treatment: use of the MASCC Oral Agent Teaching Tool (MOATT) worldwide, a review for the future. Support Care Cancer. 2025; 33:229.","DOI":"10.1007\/s00520-025-09274-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tomonaga I, Koseki H, Imai C, Shida T, Nishiyama Y, Yoshida D, Yokoo S, Osaki M. Incidence and characteristics of aspiration pneumonia in the Nagasaki Prefecture from 2005 to 2019. BMC Pulm Med. 2024; 24:191.","DOI":"10.1186\/s12890-024-03015-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Abe T, Kusakabe S, Naoi M, Suzuki T, Sagara A, Hiraide M, Sano M, Nakayama T. Evaluation of the simple suspension method for oral anticancer drugs. Yakugaku Zasshi. 2024; 144:441-445.","DOI":"10.1248\/yakushi.23-00194"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Dziewas R, Beck AM, Clave P, Hamdy S, Heppner HJ, Langmore SE, Leischker A, Martino R, Pluschinski P, Roesler A, Shaker R, Warnecke T, Sieber CC, Volkert D, Wirth R. Recognizing the importance of dysphagia: stumbling blocks and stepping stones in the twenty-first century. Dysphagia. 2017; 32:78-82.","DOI":"10.1007\/s00455-016-9746-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke. 2005; 36:2756-2763.","DOI":"10.1161\/01.STR.0000190056.76543.eb"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Pei R, Wang D. Prognostic nutritional index negative associated with mortality in older Japanese patients with dysphagia. Front Nutr. 2025; 12:1586248.","DOI":"10.3389\/fnut.2025.1586248"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. ASGE Standards of Practice Committee; Jain R, Maple JT, <i>et al<\/i>. The role of endoscopy in enteral feeding. Gastrointest Endosc. 2011; 74:7-12.","DOI":"10.1016\/j.gie.2010.10.021"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Volkert D, Berner YN, Berry E, <i>et al<\/i>. ESPEN Guidelines on Enteral Nutrition: Geriatrics. Clin Nutr. 2006; 25:330-360.","DOI":"10.1016\/j.clnu.2006.01.012"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010; 172:1092-1097.","DOI":"10.1093\/aje\/kwq224"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant. 2013; 48:452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sako A, Yasunaga H, Horiguchi H, Fushimi K, Yanai H, Uemura N. Prevalence and in-hospital mortality of gastrostomy and jejunostomy in Japan: a retrospective study with a national administrative database. Gastrointest Endosc. 2014; 80:88-96.","DOI":"10.1016\/j.gie.2013.12.006"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Boakye D, Nagrini R, Ahrens W, Haug U, Gunther K. The association of comorbidities with administration of adjuvant chemotherapy in stage III colon cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol. 2021; 13:1758835920986520.","DOI":"10.1177\/1758835920986520"},{"key":"13","unstructured":"13. Trissel LABRF, Zhang YB, Koontz SEPB. Temozolomide stability in extemporaneously compounded oral suspensions. Int J Pharm Compd. 2006; 10:396-399."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Annereau M, Hinterlang M, Bienayme H, Vassal G, Pinon A, Schmitt M, Denis L, Lemarchand C, Martin L, Lemare F, Abbou S, Bastid J, Tortolano L. Development of a hospital compounded, taste-masked, temozolomide oral suspension and 5-year real-life experience in treating paediatric patients. Pharmaceuticals (Basel). 2022; 15:555.","DOI":"10.3390\/ph15050555"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Diez BD, Statkevich P, Zhu Y, Abutarif MA, Xuan F, Kantesaria B, Cutler D, Cantillon M, Schwarz M, Pallotta MG, Ottaviano FH. Evaluation of the exposure equivalence of oral versus intravenous temozolomide. Cancer Chemother Pharmacol. 2010; 65:727-734.","DOI":"10.1007\/s00280-009-1078-6"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Almeida ND, Yu H, Iovoli AJ, Fang M, Schrand TV, Pepin A, Gupta V, Wooten KE, Markiewicz MR, McSpadden RP, Hicks WL, Jr., Farrugia MK, Singh AK. Prophylactic gastrostomy tube during chemoradiation for head and neck cancer decreases weight loss but increases rate of tube use beyond six months. Oral Oncol. 2025; 160:107136.","DOI":"10.1016\/j.oraloncology.2024.107136"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Molinaro E, Viola D, Viola N, Falcetta P, Orsolini F, Torregrossa L, Vagli P, Ribechini A, Materazzi G, Vitti P, Elisei R. Lenvatinib administered <i>via<\/i> nasogastric tube in poorly differentiated thyroid cancer. Case Rep Endocrinol. 2019; 2019:6831237.","DOI":"10.1155\/2019\/6831237"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kawano F, Yonekawa T, Yamaguchi H, Shibata N, Tashiro K, Ikenoue M, Munakata S, Higuchi K, Tanaka H, Sato Y, Hosokawa A, Takeno S, Nakamura K, Nanashima A. Nasogastric administration of lenvatinib solution in a mechanically ventilated patient with rapidly growing anaplastic thyroid cancer. Endocrinol Diabetes Metab Case Rep. 2020; 2020.","DOI":"10.1530\/EDM-20-0064"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tani N, Takatsuka S, Kataoka N, Kunimatsu Y, Tsutsumi R, Sato I, Tanimura M, Nakano T, Tanimura K, Kato D, Takeda T. Nasogastric administration of osimertinib suspension for an epidermal growth factor receptor-mutated lung cancer causing an esophageal stricture: case report. Ann Palliat Med. 2022; 11:1542-1545.","DOI":"10.21037\/apm-21-940"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Takeda T, Itano H, Takeuchi M, Nishimi Y, Saitoh M, Takeda S. Osimertinib administration <i>via<\/i> nasogastric tube in an EGFR-T790M-positive patient with leptomeningeal metastases. Respirol Case Rep. 2017; 5:e00241.","DOI":"10.1002\/rcr2.241"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ballard P, Yates JW, Yang Z, <i>et al<\/i>. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016; 22:5130-5140.","DOI":"10.1158\/1078-0432.CCR-16-0399"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Fiebrich-Westra HB, Visser O, Francken AB, Smolders EJ. Alternative routes of drug administration: exposure of imatinib using different formulations. Cancer Chemother Pharmacol. 2025; 95:45.","DOI":"10.1007\/s00280-025-04766-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Okuda T, Hayashi H, Fujita M, Yoshioka H, Tasaki T, Nakagawa K, Kato A. Administration of gefitinib <i>via<\/i> nasogastric tube effectively improved the performance status of a patient with lung adenocarcinoma-derived meningeal carcinomatosis. Int Cancer Conf J. 2014; 3:211-214.","DOI":"10.1007\/s13691-013-0148-0"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Suzumura T, Yonesaka K, Tsukuda H, Fukuoka M. Successful gefitinib treatment administration <i>via<\/i> gastrostomy tube in a patient with non-small cell lung cancer with dysphagia. BMJ Case Rep. 2014; 2014:bcr2013202705.","DOI":"10.1136\/bcr-2013-202705"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Uruga H, Moriguchi S, Takahashi Y, Ogawa K, Murase K, Mochizuki S, Hanada S, Takaya H, Miyamoto A, Morokawa N, Kishi K. Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis. BMC Cancer. 2018; 18:825.","DOI":"10.1186\/s12885-018-4743-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Cantarini MV, McFarquhar T, Smith RP, Bailey C, Marshall AL. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation <i>via<\/i> drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. Clin Ther. 2004; 26:1630-1636.","DOI":"10.1016\/j.clinthera.2004.10.011"},{"key":"27","unstructured":"27. Okita A, Miyade Y, Okano K. Effective management of an advanced gastric cancer patient by TS-1 combined chemotherapy using nasojejunal tube and successful transfer to home care after percutaneous transesophageal gastro-tubing (PTEG): a case report. Acta Med Okayama. 2010; 64:67-70."},{"key":"28","unstructured":"28. Hirano K, Nakamura K, Hasegawa M. Pharmacokinetics and adverse event of TS-1 administered through gastrostomy. Gan To Kagaku Ryoho. 2005; 32:859-862."},{"key":"29","unstructured":"29. Hagiike M, Tsuboi Y, Akamoto S, Yachida S, Izuishi K, Karasawa Y, Goda F, Okada S, Usuki H, Maeta H. TS-1 therapy <i>via<\/i> intestinal catheter used for tube feeding in a patient with gastric cancer after total gastrectomy. Gan To Kagaku Ryoho. 2005; 32:1033-1036."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Thomas QD, Pautas M, Guilhaume MN, Fiteni F, Ge T, Girard N. Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report. Medicine (Baltimore). 2021; 100:e27611.","DOI":"10.1097\/MD.0000000000027611"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kanai O, Kim YH, Nakatani K, Fujita K, Mio T. Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance status. Clin Case Rep. 2017; 5:927-930.","DOI":"10.1002\/ccr3.973"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Alsuliman T, Belghoul M, Choufi B. Ibrutinib treatment through nasogastric tube in a comatose patient with central nervous system localization of mantle cell lymphoma. Case Rep Hematol. 2018; 2018:5761627.","DOI":"10.1155\/2018\/5761627"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Bosch-Barrera J, Sais E, Lorencio C, Porta R, Izquierdo A, Menendez JA, Brunet J, Sirvent JM, Rosell R. Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. Lung Cancer. 2014; 86:102-104.","DOI":"10.1016\/j.lungcan.2014.07.010"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Yoshioka H, Okuda T, Nakao T, Fujita M, Takahashi JC. Experience with tirabrutinib in the treatment of primary central nervous system lymphoma that is difficult to treat with standard treatment. Anticancer Res. 2022; 42:4173-4178.","DOI":"10.21873\/anticanres.15917"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Yoshioka H, Okuda T, Nakao T, Fujita M, Takahashi JC. Experience with nasogastric tube administration of tirabrutinib in the treatment of an elderly patient with primary central nervous system lymphoma. Int Cancer Conf J. 2021; 10:290-293.","DOI":"10.1007\/s13691-021-00491-1"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sato H, Kobayashi T, Fujita N, Yamashita T, Kitadate A, Yoshioka T, Nara M, Kameoka Y, Miura M, Takahashi N. Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin <i>via<\/i> percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia. Cancer Chemother Pharmacol. 2022; 90:279-284.","DOI":"10.1007\/s00280-022-04460-0"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Sugiura S, Asano M, Kinoshita K, Tanimura M, Nabeshima T. Risks to health professionals from hazardous drugs in Japan: a pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. J Oncol Pharm Pract. 2011; 17:14-19.","DOI":"10.1177\/1078155209358632"},{"key":"38","unstructured":"38. Managing Hazardous Drug Exposures: Information for Healthcare Settings. <i>https:\/\/www.cdc.gov\/niosh\/docs\/2023-130\/default.html<\/i>\u3000(accessed December 4, 2025)."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Power LA, Coyne JW. ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm. 2018; 75:1996-2031.","DOI":"10.2146\/ajhp180564"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/6\/19_2025.01095\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:19:59Z","timestamp":1768018799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/6\/19_2025.01095\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2025.01095","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"article-number":"2025.01095"}}